Alnylam ATTR Program on Track as Company Explores Subcutaneous Delivery for Cholesterol Drug | GenomeWeb

Alnylam Pharmaceuticals this week provided new guidance on its key drug-development programs, noting that its flagship transthyretin-mediated amyloidosis therapy ALN-TTR02 remains poised to enter phase III testing by the end of next year, and that the development of a subcutaneous version of its hypercholesterolemia treatment ALN-PCS has given a boost to partnership discussions around the drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.